Markets:

Overview

News

Currencies

International

Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

175.66 +0.46 (+0.26%)

Streaming Delayed Price Updated: 9:30 AM EST, Nov 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >

Why Are AstraZeneca Shares Trading Higher Today ↗

February 15, 2022

Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease...

Via Benzinga

AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21 ↗

February 10, 2022

AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 63% Y/Y to $12.0

Via Benzinga

AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences ↗

February 03, 2022

AstraZeneca plc (NASDAQ: AZN) has granted

Via Benzinga

Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial ↗

January 25, 2022

Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is...

Via Benzinga

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows ↗

January 24, 2022

A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ...

Via Benzinga

Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder ↗

January 24, 2022

The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for...

Via Benzinga

Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg ↗

January 21, 2022

According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine...

Via Benzinga

AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer ↗

January 19, 2022

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable...

Via Benzinga

AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US ↗

January 13, 2022

AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-...

Via Benzinga

AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use ↗

January 13, 2022

AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third...

Via Benzinga

Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies ↗

January 13, 2022

Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron...

Via Benzinga

Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins ↗

January 13, 2022

AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines...

Via Benzinga

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact ↗

January 03, 2022

Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small...

Via Benzinga

Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron ↗

December 23, 2021

A three-dose course of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the omicron coronavirus variant, data from an Oxford University lab...

Via Benzinga

AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma ↗

December 20, 2021

The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult...

Via Benzinga

Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study ↗

December 17, 2021

COVID-19 vaccines from China's state-owned Sinopharm and Johnson & Johnson (NYSE: JNJ) and Russia developed Sputnik were found to produce little or no...

Via Benzinga

AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant ↗

December 16, 2021

New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against...

Via Benzinga

Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back ↗

December 15, 2021

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year....

Via Benzinga

Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy ↗

December 14, 2021

Samsung Biologics Co Ltd said it would continue its partnership with AstraZeneca Plc (NASDAQ: AZN) on manufacturing biopharmaceuticals. According to Samsung, the production...

Via Benzinga

AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK ↗

December 10, 2021

On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor...

Via Benzinga

Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity ↗

December 09, 2021

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an...

Via Benzinga

AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised ↗

December 09, 2021

The FDA authorized the use of AstraZeneca Plc's (NASDAQ: AZN)antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a...

Via Benzinga

Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response ↗

December 07, 2021

A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or ...

Via Benzinga

Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder ↗

December 07, 2021

Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and...

Via Benzinga

Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population ↗

December 03, 2021

Valneva SE (NASDAQ: VALN) has responded to data published from the U.K COV-Boost COVID-19 vaccine trial that investigated the reactogenicity and immunogenicity of...

Via Benzinga

AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report ↗

December 03, 2021

AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by...

Via Benzinga

Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots ↗

December 02, 2021

Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to...

Via Benzinga

AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting ↗

November 30, 2021

The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer....

Via Benzinga

AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance ↗

November 12, 2021

AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new...

Via Benzinga

AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report ↗

November 10, 2021

AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Astrazeneca Plc Ord (OP:AZNCF)

All News about Astrazeneca Plc Ord

Starting at $3.75/week.

Subscribe Today